Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

BACKGROUND: Although number of elderly patients with metastatic colorectal cancer (mCRC) is rapidly increasing, this population is often underrepresented in clinical trials. Recently, a phase II trial demonstrated that capecitabine and oxaliplatin (XELOX) combined with bevacizumab XELOX plus bevaciz...

Descripción completa

Detalles Bibliográficos
Autores principales: Munemoto, Yoshinori, Kanda, Mitsuro, Ishibashi, Keiichiro, Hata, Taishi, Kobayashi, Michiya, Hasegawa, Junichi, Fukunaga, Mutsumi, Takagane, Akinori, Otsuji, Toshio, Miyake, Yasuhiro, Nagase, Michitaka, Sakamoto, Junichi, Matsuoka, Masaki, Oba, Koji, Mishima, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619505/
https://www.ncbi.nlm.nih.gov/pubmed/26497654
http://dx.doi.org/10.1186/s12885-015-1712-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619505/
https://www.ncbi.nlm.nih.gov/pubmed/26497654
http://dx.doi.org/10.1186/s12885-015-1712-0

Ejemplares similares